Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

2478 - ANSELMA: ANtiangiogneic SEcond line Lung cancer Meta-Analysis in non-small cell lung cancer (NSCLC)


08 Oct 2016


Poster Display


JORDI Remon Masip


Annals of Oncology (2016) 27 (6): 416-454. 10.1093/annonc/mdw383


J. Remon Masip1, C. Thuong2, J. Pignon3, B. Lacas3, J. Soria1, B. Besse1

Author affiliations

  • 1 Medicine - Oncologie Thoracique, Institut Gustave Roussy, 94805 Villejuif - Villejuif/FR
  • 2 Bioestatisitics, Institut Gustave Roussy, 94805 Villejuif - Villejuif/FR
  • 3 Service De Biostatistique Et D’epidemiologie, Gustave Roussy Cancer Campus, FR-94805 - Villejuif/FR


Abstract 2478


Only 20% of NSCLC patients have a response to immune checkpoint inhibitors as second-line treatment. Several randomized phase II and III trials have tested the efficacy of the combination of antiangiogenic drugs (AD) plus chemotherapy (CT) or erlotinib (E) with inconsistent benefit. We performed a meta-analysis to validate the efficacy of these agents as strategy second-line option in advanced NSCLC patients.


Randomized trials of AD plus standard second-line treatment, CT (docetaxel [Do], pemetrexed) or E compared to same standard treatment ending accrual before 2015 were included based on search of publication databases, abstract proceedings and trial registers. Data were extracted from publications. Random-effect models, in case of significant heterogeneity (Het), fixed-effect model otherwise, were used to compute pooled hazard ratios (HRs) for overall survival (OS, primary end-point) and PFS and pooled odds ratios (ORs) for response rate (RR) and adverse events. Het was studied using Q-test I2.


seventeen trials with 8,703 patients were included with 3 types of combinations: 5 trials monoclonal antibodies AD + CT (Do for 5), 7 on tyrosine kinase inhibitor (TKI) AD + CT (Do for 3) and 5 AD (TKI for 4) + E. Trial size ranged from 100 to 1391 patients. ADs evaluated were: cabozantinib (1 trial), aflibercept (1), nintedanib (2), ramucirumab (2), sorafenib (2), bevacizumab (3), vandetanib (3), sunitinib (3). Control arm was docetaxel (8 trials), pemetrexed (4), E (5). Compared with standard second-line treatment alone, AD significantly prolonged OS (HR 0.94 [95% confidence interval 0.89-0.99, random-effect model; P = 0.03; P-Het = 0.004), PFS (0.79; [0.73- 0.85], random effect model; P 


Antiangiogenic drugs significantly prolong OS and PFS when added to standard second-line treatment in advanced NSCLC patients. Toxicity results will be presented during the congress

Clinical trial identification

Legal entity responsible for the study



Gustave Roussy


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings